Stock screenerAll disclosures →
EDGAR →
ZYME
Conviction 32HealthcareScan · Thu, Jun 25, 2026ZYME$23.76-2.22%
ResistanceSupportVol 14Vol MA14 647.43K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price23.76
Change-2.22%
Gap-0.62%
Rel volume0.83×
Avg volume705.42K
Avg $ vol16.77M
SMA 2023.79
SMA 5025.28
SMA 20023.00
Price vs 50-6.00%
Price vs 200+3.32%
MA stackmixed
50/200 cross—
Supertrenddown · 25.67
RSI (14)48
MACD hist0.14
MACD crossbull · 2d
Stoch %K / %D54 / 59
ADX (14)20
+DI / −DI19 / 18
RSI divergence—
MACD divergence—
ATR %+4.15%
ADR %3.75%
52w high28.56
52w low12.02
From 52w high-16.81%
Above 52w low+97.67%
New 52w highNo
SqueezeOff
Bollinger width13.80%
%B0.49
Donchian pos46.55%
Donchian high25.62
Donchian low22.14
AVWAP (52w high)24.72
vs AVWAP high-3.90%
AVWAP (52w low)22.48
vs AVWAP low+5.70%
OBV trendFlat
Chaikin MF (20)-0.12
Today vs 20d0.83×
Avg vol (14d)647.43K
Avg vol (20d)705.42K
Avg $ vol (20d)16.77M
Market cap1.74B
RS 3m (vs SPY)-9.29%
RS 6m (vs SPY)-18.50%
RS line new highNo
Trend template5/8
Technical rank37.1
1 week+2.68%
1 month-6.46%
3 months-1.94%
6 months-13.98%
1 year+85.34%
YTD-10.74%
P/E-21.39
P/B10.61
P/S16.37
P/FCF-50.25
EPS-1.08
Div yield—
ROE-49.59%
ROA-16.97%
Debt/Eq—
Current10.82
EV/EBITDA—
Gross margin—
Net margin-76.56%
Rev growth38.87%
EPS growth33.88%
Price target38.71
Target upside62.92%
Analyst ratingBuy
Institutional99.71%
Ent. value1.49B
Revenue2.41M
Net income-44.16M
Gross profit—
Free cash flow-34.53M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out73.02M
Employees264
ListedFri, Apr 28, 2017
Free float45.96M
Float %62.3%
Short interest4.53M
Days to cover7.6d
Short volume64.2%
Squeeze score61 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.39 · 5 est
Last EPS vs est−$0.59 vs −$0.10
Last surprise-490.0% miss
Setup gradeD
Conviction32 / 100
Pattern quality—
Tech rank37.1 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance27.08
Support22.22
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in ZYME
No recent disclosed trades by Congress in ZYME. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ZYME · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Schneider Paul R EVP, General Counsel · Stock Option (Right to Buy) · 2026-05-13 | Grant | 178K | $0 | 2026-05-13 | 2026-05-15 |
Schneider Paul R EVP, General Counsel · Restricted Stock Unit · 2026-05-13 | Grant | 119K | $0 | 2026-05-13 | 2026-05-15 |
Schayowitz Adam See Remarks · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
SEC filings
EDGAR filings in ZYME
No recent SEC filings on file for ZYME.
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.